Takeda sues generics makers over heartburn drug; EU wants to tighten up Trobalt use;

@FiercePharma: ICYMI: Bristol-Myers, AstraZeneca win turnabout at NICE for Forxiga. Diabetes med now backed in some regimens. More | Follow @FiercePharma

@EricPFierce: Will Hospira never learn? FDA warning letter says some problems at India plant same as those recently noted at Rocky Mount. Report | Follow @EricPFierce

@CarlyHFierce: Are corruption/lax regulation in Serbia to blame for lack of interest in Galenika? Valeant the only bidder. Article | Follow @CarlyHFierce

> Japan's Takeda sued generics makers Impax Labs ($IPXL), TWi Pharmaceuticals and Sandoz, a Novartis ($NVS) unit, for stepping on its patent for the acid reflux treatment Dexilant. Report

> European drug regulators called for restrictions on use of Trobalt, an epilepsy drug sold by GlaxoSmithKline ($GSK), after some patients reported abnormal coloring of skin, nails and retina. Report

> Teva Pharmaceutical ($TEVA) said the FDA has accepted its application for less-frequent dosing of its multiple sclerosis drug Copaxone; the proposal would allow twice the usual dose to be given three times a week. Report

> Novo Nordisk ($NVO) asked European regulators to approve Ideglira, a combination drug comprising its insulin drug Tresiba and GLP-1 analogue Victoza. Report

> Federal agencies were instructed to cut their 2015 budget requests 5% more than President Obama outlined to them in April. Report

Medical Device News

@FierceMedDev: Smiths eyes $3B-plus medical biz sale. Report | Follow @FierceMedDev

 @DamianFierce: If you're a hospital and can prove Covidien's oximeters beat Masimo's, you may be due $1 million. Story | Follow @DamianFierce

@MichaelGFierce: Roche, Cook help launch public-private Indiana research institute. Article | Follow @MichaelGFierce

> Mercator raises $6.5M for microinfusion tech. Story

> OmniVision's income, revenue jump in billion-dollar year. News

> Smiths mulls $3B-plus medical biz sale. Article

> Qiagen eyes companion diagnostics with cancer deals. More

Biotech News

@FierceBiotech: ICYMI: Top 10 experimental cancer drugs - 2013. Special report | Follow @FierceBiotech

@JohnCFierce: Discounting wins NICE recommendation for Eylea, another score for Regeneron/Bayer. Report | Follow @JohnCFierce

@RyanMFierce: Satori Pharmaceuticals shuts down after failure of Alzheimer's drug. News | Follow @RyanMFierce

 @EmilyMFierce: Japan launches public-private consortium to hunt for new drugs for infectious diseases. Item | Follow @EmilyMFierce

> Lung cancer spotlighted as prime target for new immunotherapies. Article

> FDA snubs Endo's testosterone drug over REMS concerns. News

> Epizyme scores latest biotech IPO victory to advance cancer pipeline. Story

And Finally... Adding weight loss to treatment for psoriasis helped ease symptoms. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.